Your browser doesn't support javascript.
loading
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Matulonis, U A; Shapira-Frommer, R; Santin, A D; Lisyanskaya, A S; Pignata, S; Vergote, I; Raspagliesi, F; Sonke, G S; Birrer, M; Provencher, D M; Sehouli, J; Colombo, N; González-Martín, A; Oaknin, A; Ottevanger, P B; Rudaitis, V; Katchar, K; Wu, H; Keefe, S; Ruman, J; Ledermann, J A.
Afiliação
  • Matulonis UA; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, USA. Electronic address: Ursula_Matulonis@dfci.harvard.edu.
  • Shapira-Frommer R; Oncology Institute and Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel.
  • Santin AD; Obstetrics, Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, USA.
  • Lisyanskaya AS; Department of Gynaecological Oncology, City Clinical Oncology Dispensary, Saint Petersburg, Russia.
  • Pignata S; Department of Urogynaecological Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G Pascale", IRCCS, Naples, Italy.
  • Vergote I; Department of Obstetrics and Gynaecology and Gynaecologic Oncology, University Hospital Leuven, Leuven, Belgium.
  • Raspagliesi F; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Birrer M; Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, USA.
  • Provencher DM; Hôpital Notre-Dame - Pavillon L-C Simard, Centre Hospitalier de L'Université de Montréal (CHUM), Montreal, Canada.
  • Sehouli J; Gynecology and Obstetrics, Charité-Medical University of Berlin, Berlin, Germany.
  • Colombo N; Department of Surgical Sciences, University of Milano-Bicocca and European Institute of Oncology, Milano, Italy.
  • González-Martín A; Medical Oncology, Clinica Universidad de Navarra; formerly of MD Anderson International España, Madrid.
  • Oaknin A; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Ottevanger PB; Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Rudaitis V; Clinic of Obstetrics and Gynecology, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania.
  • Katchar K; Companion Diagnostics, Merck & Co., Inc, Kenilworth, USA.
  • Wu H; BARDS, MSD China, Beijing, China.
  • Keefe S; Clinical Development, Merck & Co., Inc., Kenilworth, USA.
  • Ruman J; Clinical Development, Merck & Co., Inc., Kenilworth, USA.
  • Ledermann JA; UCL Cancer Institute and UCL Hospitals, Department of Oncology, University College London, London, UK.
Ann Oncol ; 30(7): 1080-1087, 2019 07 01.
Article em En | MEDLINE | ID: mdl-31046082
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Adenocarcinoma de Células Claras / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Adenocarcinoma de Células Claras / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2019 Tipo de documento: Article